Cargando…

In Vitro Activity of Ceftaroline and Comparators against Bacterial Isolates Collected Globally from Patients with Skin and Soft Tissue Infections: ATLAS Program 2019–2020

The objective of this study was to assess the in vitro activity of ceftaroline and a panel of comparator agents against isolates causing skin and soft tissue infections (SSTIs) collected in Africa/Middle East, Asia–Pacific, Europe, and Latin America from 2019–2020. Minimum inhibitory concentrations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuraieva, Alona, Cabezas-Camarero, Guillermo, Kiratisin, Pattarachai, Utt, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451970/ https://www.ncbi.nlm.nih.gov/pubmed/37627657 http://dx.doi.org/10.3390/antibiotics12081237

Ejemplares similares

Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia
por: Torres, Antoní, et al.
Publicado: (2023)

1245. In Vitro Activities of Ceftaroline and Comparator Agents Against Bacterial Pathogens Collected from Patients with Skin and Skin Structure Infections: ATLAS Global Surveillance Program 2012-2019
por: Hackel, Meredith, et al.
Publicado: (2021)

1565. In Vitro Activities of Ceftaroline and Comparator Agents against Bacterial Pathogens Collected from Patients with Skin and Skin Structure Infections: ATLAS Global Surveillance Program 2012-2018
por: Hackel, Meredith, et al.
Publicado: (2020)

Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia
por: Mpenge, Mbiye A, et al.
Publicado: (2015)

Ceftaroline in complicated skin and skin-structure infections
por: Hernandez, Paul O, et al.
Publicado: (2012)

Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections
por: Das, Shampa, et al.
Publicado: (2019)

Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections
por: Goodman, Julian J, et al.
Publicado: (2012)

Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience
por: Santos, Paul D, et al.
Publicado: (2013)

678 Ceftaroline vs Vancomycin in Treatment for Skin and Soft Tissue Infections (SSTI) in Obese Patients
por: Nguyen, Hao, et al.
Publicado: (2014)

Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia
por: Esposito, Susanna, et al.
Publicado: (2021)

Genetic Characterization of Carbapenem-Resistant Enterobacteriaceae and the Spread of Carbapenem-Resistant Klebsiella pneumonia ST340 at a University Hospital in Thailand
por: Netikul, Thidarat, et al.
Publicado: (2015)

Ceftaroline
por: Soriano, Alex
Publicado: (2021)

Correction to: Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia
por: Esposito, Susanna, et al.
Publicado: (2021)

Ceftaroline Fosamil for the Treatment of Staphylococcus aureus Bacteremia Secondary to Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia
por: Vazquez, Jose A., et al.
Publicado: (2015)

Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017–2019
por: Gales, Ana C, et al.
Publicado: (2023)

Stenotrophomonas maltophilia Infections: Clinical Characteristics and Factors Associated with Mortality of Hospitalized Patients
por: Insuwanno, Worachart, et al.
Publicado: (2020)

679 Ceftaroline Fosamil (CPT-F) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in Obese Patients
por: Kaye, Keith, et al.
Publicado: (2014)

2376. In Vitro Activities of Ceftaroline and Comparator Agents Against Bacterial Pathogens Collected From Patients With Skin and Skin Structure Infections in Latin America: AWARE Surveillance Program 2017
por: Hackel, Meredith, et al.
Publicado: (2018)

Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019
por: Adámková, V, et al.
Publicado: (2022)

In vitro Activity of Ceftaroline Against Pathogens Collected Globally from the AWARE Surveillance Program, 2016
por: Hackel, Meredith, et al.
Publicado: (2017)

Epidemiology of bacteremia caused by uncommon non-fermentative gram-negative bacteria
por: Rattanaumpawan, Pinyo, et al.
Publicado: (2013)

1224. In vitro Activities of Ceftaroline and Comparator Agents against Gram-positive Bacterial Pathogens Causing Blood Stream Infections in a Global Population: ATLAS Surveillance Program 2012-2019
por: Hackel, Meredith, et al.
Publicado: (2021)

Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia
por: Maselli, Diego J, et al.
Publicado: (2012)

Ceftaroline Efficacy and Safety in Treatment of Complicated Skin and Soft Tissue Infection: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
por: Lan, Shao-Huan, et al.
Publicado: (2019)

Activity of ceftaroline and comparators against pathogens isolated from skin and soft tissue infections in Latin America – results of AWARE surveillance 2012
por: Hoban, Daryl, et al.
Publicado: (2015)

Implementation of global antimicrobial resistance surveillance system (GLASS) in patients with bacteremia
por: Sirijatuphat, Rujipas, et al.
Publicado: (2018)

The use of extrapolation based on modeling and simulation to support high‐dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft‐tissue infections
por: Chan, Phylinda L.S., et al.
Publicado: (2021)

Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010
por: Flamm, Robert K., et al.
Publicado: (2013)

Emergence of Francisella novicida Bacteremia, Thailand
por: Leelaporn, Amornrut, et al.
Publicado: (2008)

Dyella japonica Bacteremia in Hemodialysis Patient
por: Kiratisin, Pattarachai, et al.
Publicado: (2007)

Pseudoclavibacter Otitis Media in a 3-Year-Old Boy With Pulmonary and Spinal Tuberculosis
por: Ayuthaya, Satja Issaranggoon na, et al.
Publicado: (2015)

Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections
por: Palavutitotai, Nattawan, et al.
Publicado: (2018)

Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial
por: Rattanaumpawan, Pinyo, et al.
Publicado: (2017)

Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit
por: Maggiore, Christy, et al.
Publicado: (2015)

809 Contemporary Experience with Ceftaroline Fosamil for the Treatment of Community-acquired Bacterial Pneumonia
por: Johnson, Leonard B, et al.
Publicado: (2014)

Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011)
por: Flamm, Robert K., et al.
Publicado: (2014)

Epidemiology of Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Study, 2018 to 2019
por: Estabrook, Mark, et al.
Publicado: (2023)

Ceftaroline-related acute eosinophilic pneumonia
por: Min, Zaw, et al.
Publicado: (2021)

Ceftaroline in severe community-acquired pneumonia
por: Cilloniz, Catia, et al.
Publicado: (2022)

A Case of Ceftaroline-Associated Thrombocytopenia
por: Jagadish, Ashwin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lrp9agphhvo4p2mm8huq6rvee6